Stephen Ubl, AdvaMed, and John Babitt, Ernst & Young head of Medtech for Americas, share insight on rising medical technology costs.

He said the tax would leave companies with "two very bad choices" — reduce jobs and spending on research and development or pass the cost of the tax on to consumers, which "would raise the cost of care and potentially undermine one of the primary goals of health-care reform."

There are over two million Americans employed by the medical-technology sector in "high-paying, high-tech jobs," Ubl said. "We need more of them. So the tax is counterproductive to those [job-creation] efforts."

These companies are "poised to introduce incredible technologies that are going to improve people’s lives," he said, at a time of "macroeconomic headwinds" and a U.S. regulatory environment that is not competitive, uncertain, unpredictable and untimely.

In the same interview, John Babitt, head of medical-technology practice for the Americas at Ernst & Young, said the tax might drive medical-technology companies to look overseas in deciding "where to establish headquarters, where to establish R&D." He said 60 percent of medical-technology revenue comes from outside the U.S., making the industry "good exporting companies."